Market Intelligence Resource | April 8, 2011

FDA Clinical Review of Invega sNDA for Pediatric Use

April 8, 2011 The U.S. Food and Drug Administration (FDA) had approved the use of Invega for adults with schizophrenia in 2006. The FDA has recently approved Invega, an atypical antipsychotic, for use by adolescents between the age of 12- and 17-years old diagnosed with schizophrenia. Download the Report . . .

Want To Read More? Log In Or Become A Paid Member

Resource Available For Paid OPEN MINDS Circle Members Only

Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.